- 27 years oncology Drug Development experience in pharma. - worked for both large & small pharmas; biotech & cros. - 6 years international experience based in brussels (bms). - global team Leadership in a highly matrixed environment. my personal goal: 1 in 3 of us will face Cancer during our lives. we desperately need new treatments for all types of cancers. my goal is to help develop new Cancer treatments to meet the unmet needs of Cancer patients worldwide. i have had the great opportunity to lead the late stage clinical study for votrient (pazopanib) in advanced soft tissue sarcoma. specialties: worked across all phases of oncology Drug Development. development experience includes taxanes, Monoclonal Antibodies, novel biologics; Monoclonal Antibodies and cytoprotective agents. managed global Clinical trials in lung, breast; genitourinary; gastro-intestinal and solid tumours (with experience from first in man to registration and into Phase IV). active Member of asco and esmo. broad experience in developing clinical Strategy and plans for novel therapeutics.
Director - Clinical Development Oncology - Global Medical Affairs
Since March 2015
i have become part of novartis oncology following the completion of the recent purchase of gsk oncology by novartis. i continue to support votrient (pazopanib) for both rcc & sts indications I have become part of Novartis Oncology following the completion of the recent purchase of GSK Oncology by Novartis. I continue to support Votrient (Pazopanib) for both RCC & STS indications
Director - Oncology Global Medical AffairsJanuary 2012 --- March 2015
Member of the votrient global medical team supporting global medical activities for the soft tissue sarcoma indication. i also support votrient medical teams for asia pac / emerging markets / japan.
Director / Clinical LeaderSeptember 2006 --- January 2012
votrient™ (pazopanib) Clinical indication Leader for sarcoma and Clinical lead for the Phase III (palette) study team. the successful Phase III study was recently published in the lancet - http://www.thelancet.com/journals/lancet/article/piis0140-6736(12)60651-5/abstract throughout 2009 i worked for oncology R&D in the apjem (asia pacific - japan - emerging markets) team, and returned to palette team in 2010.
Oncology Group LeaderJanuary 1995 --- January 1997
Clinical ScientistJanuary 1990 --- January 1995
LinkedIn Assessment :
M.Sc in Chemistry (Analytical Toxicology & Pharmacology) from University of Greenwich in 1988
in from Bedford School in 1977
Area / Region
London, United Kingdom